AMGN · News · 20260903N
Repatha Cardiovascular Outcomes Data
AMGEN INC · 2026-09-03 · Importance 54 · Surprise 74 · In source text
Amgen reported secondary VESALIUS-CV analysis showing Repatha reduced all-cause mortality by 20% and myocardial infarction risk by 36% in high-risk adults without a prior heart attack or stroke. The findings support earlier use of the PCSK9 inhibitor and could expand its addressable cardiovascular market. Uptake remains constrained because many patients do not reach guideline-recommended LDL-C levels, while payer access, guideline adoption, and reluctance to use an injectable may affect commercialization.
Key facts
- A subanalysis of the Vesalius-CV trial demonstrated a 36% reduction in myocardial infarction risk with Repatha. source
- Amgen's Chief Medical Officer Paul Burton said Repatha is at an 'inflection' point due to new data showing reductions in cardiovascular risks and all-cause mortality. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | A subanalysis of the Vesalius-CV trial demonstrated a 36% reduction in myocardial infarction risk with Repatha. |